THE EFFECT OF L-ARGININE ON OXIDATIVE STRESS AND MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

L. P. Martynyuk, L. Z. Vons, O. O. Ruzhytska
I. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE

Background. Diabetic kidney disease (DKD) is one of the severest complications of diabetes. Microalbuminuria (MAU) is one of the first signals of DKD and an important pathogenetic mechanism of disease progression. With diabetes antioxidant properties worsen significantly.

Objective. The aim was to investigate the effect of L-arginine on oxidative stress parameters and microalbuminuria in type 2 diabetes mellitus and chronic kidney disease patients.

Methods. In total, 57 patients with type 2 diabetes mellitus and chronic kidney disease and 30 healthy individuals (control group) took part in the study. The patients were divided into 2 congruent groups. The 1-st group of patients (n=33), in addition to standard therapy, received L-arginine 4.2 g intravenously for 5 days, after that they took it 1.0 g orally three times a day during meals for 1 month. The second group of patients (n=24) received a standard therapy.

The concentration of lipid peroxidation products was measured by a spectrophotometric method. The determination of MAU was carried out in morning portion of urine immunological semiquantitative using test strips.

Results. Significant improvement in indexes of lipid peroxidation was observed in both groups after therapy (p<0.01), but in patients treated with L-arginine it was more expressed (p<0.01). The standard therapy did not significantly affect the level of MAU (p>0.05). The patients treated with L-Arginine, showed a significant reduction in MAU (p<0.01).

Conclusions. L-arginine facilitates the correction of lipid peroxidation processes and reduces the severity of microalbuminuria in patients with diabetic kidney disease that slows down its progression.

KEY WORDS: diabetes mellitus, chronic kidney disease, lipid peroxidation, microalbuminuria, L-arginine.

Introduction

In recent decades a number of patients with diabetes mellitus (DM) is increased, the patients with type 2 diabetes mellitus are a significant share of them [1, 2, 3].

Diabetic kidney disease (DKD) is one of the severest complications of diabetes; it is registered in 20–30% of patients with diabetes. Among the patients, who receive renal replacement therapy, the share of people with DKD is about 40–50% [2, 4]. It is established that 10-20% of patients with diabetes die from chronic renal failure [4, 5].

Microalbuminuria (MAU) is one of the first signals of DKD. It is not only the symptoms but also an important pathogenetic mechanism of progression [6, 7]. According to recent studies, MAU is considered to be an independent predictor of progressive renal disease [6, 7]. Despite the fact that MAU is regarded as a risk factor, in the timely diagnosis and adequate treatment it can achieve the level of recourse normoalbuminuric [6, 8]. But in 30–45% of patients over 10 years old the disease progresses to proteinuria. On the other hand, in 20% of patients over 20 years old a terminal kidney failure is developing either [6, 7].

With diabetes antioxidant properties worsen significantly. The activity of antioxidant defence in the tissues is reduced; a lipid peroxidation is disordered that has repeatedly been proven in experimental diabetes [9, 10]. It is important to reveal as soon as possible the disorders of pro- and antioxidant system for diagnosis and monitoring of the health state. The timely correction of changes can prevent the progression of vascular complications of diabetes [9].
The aim of our research was to investigate the effect of L-arginine on oxidative stress parameters and microalbuminuria in type 2 diabetes mellitus and chronic kidney disease patients.

Methods
A total of 57 patients with type 2 diabetes mellitus and I-V stages of chronic kidney disease took part in the study. There were 27 (47%) men and 30 (53%) women among them. The average age of the patients was (58.7±1.2) years old. The average duration of diabetes is (11.4±0.9) years. The average illness period of CKD is (2.5±0.3) years. The average weight of patients was (81.7±1.4) kg. 30 healthy individuals composed the control group.

The diagnosis was established by the Second National Congress which was adopted as Nephrology classification of diseases of the urinary system in 2005. The stage of CKD was determined by glomerular filtration rate (GFR), defined by the formula CKD-EPI [11].

The concentration of thiobarbituric acid reactive substances (TBARS) was determined in the blood serum by a spectrophotometric method [12]. We also evaluated the concentrations of glutathione (SH-group) [13], catalase [14], superoxide dismutase (SOD) [15] in the blood plasma.

The determination of MAU was carried out in morning portion of urine immunological semiquantitative using test strips CLINITEK® Microalbumin 2 Strips (Germany) by means of the unit CLINITEK Status® + Analyser (Germany). MAU was diagnosed at the level of urinary albumin excretion within 30–300 mg/day, normoalbuminuria – less than 30 mg/day.

The patients with DKD were divided into 2 congruent groups: the 1-st group of patients (n=33), who, in addition to standard therapy received L-arginine 4.2 g intravenously for 5 days, after that they took it 1.0 g orally three times a day during meals for 1 month. The second group of patients (n=24) received a standard therapy. The results were compared with those of the healthy controls (n 30).

The data were subjected to statistical research processing. For this purpose the application package Statistica (StartSoft USA, v.12) was used: the method of parametric and non-parametric statistics, Spearman rank correlation to determine the connection between the studied parameters. Statistically significant differences in p<0.05 are considered.

Results
Analyzing the results, it was found out that 100% of patients with DKD have lipid peroxidation disorders (Fig. 1).

The average level of MAU in the DKD patients before treatment is in 25.6 times higher than in the control group (Fig. 2).

We have analysed the findings of MAU, depending on the method of treatment in DKD patients groups before and after treatment (Table 2).

Discussion
The average levels of TBARS and SH-groups in the patients with DKD before treatment were significantly increased compared with the corresponding values in the control group (p<0.01). Significantly reduced SOD and catalase activity were detected in the observed DKD patients before treatment compared with the control group (p<0.01). No significant difference in lipid peroxidation indexes was noted between two DKD patients groups before treatment (p>0.05). Significant improvement in lipid peroxidation indexes was observed in both DKD patients groups after therapy (p<0.01), but in the pa-

Fig. 1. The level of lipid peroxidation indexes in DKD patients before treatment and control groups.
* - The difference between the control group and DKD patients group is significant (p<0.01).

Fig. 2. The level of MAU in the DKD patients before treatment and in the control groups.
* - The difference between the control group and the DKD patients group is significant (p<0.01)
The effects of treatment on lipid peroxidation indexes are presented in Table 1.

**Table 1. The dynamics of lipid peroxidation indexes in DKD patients before and after treatment depending on different treatment regimens, M±m**

<table>
<thead>
<tr>
<th>Indexes</th>
<th>Groups</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group I (n=33)</td>
<td>Group II (n=24)</td>
</tr>
<tr>
<td><strong>TBARS, mkmol/l</strong></td>
<td>Before treatment</td>
<td>6.26±0.20</td>
</tr>
<tr>
<td></td>
<td>After treatment</td>
<td>3.81±0.27</td>
</tr>
<tr>
<td><strong>SOD, %</strong></td>
<td>Before treatment</td>
<td>41.76±0.68</td>
</tr>
<tr>
<td></td>
<td>After treatment</td>
<td>55.61±1.42</td>
</tr>
<tr>
<td><strong>SH-groups, mmol/l</strong></td>
<td>Before treatment</td>
<td>42.59±1.23</td>
</tr>
<tr>
<td></td>
<td>After treatment</td>
<td>57.05±1.98</td>
</tr>
<tr>
<td><strong>Catalase, %</strong></td>
<td>Before treatment</td>
<td>53.74±2.16</td>
</tr>
<tr>
<td></td>
<td>After treatment</td>
<td>31.39±2.80</td>
</tr>
</tbody>
</table>

**Table 2. The dynamics of MAU levels, depending on different treatment regimens, M±m**

<table>
<thead>
<tr>
<th>MAU mg/day</th>
<th>Groups</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group I (n=23)</td>
<td>Group II (n=24)</td>
</tr>
<tr>
<td>Before treatment</td>
<td>180.7±19.9</td>
<td>188.6±15.6</td>
</tr>
<tr>
<td>After treatment</td>
<td>51.4±15.9</td>
<td>149.2±15.5</td>
</tr>
</tbody>
</table>

Notes:
1. P₁ – significant difference in performance between groups before and after treatment.
2. P₂ – significant difference in performance in the first group before and after treatment.

In our present research L-arginine supplementation, which stimulates nitric oxide synthesis, causes a pronounced improvement in lipid peroxidation indexes and a significant reduction in MAU in the patients with DKD.

**Conclusions**

In patients with DKD, the decrease in activity of SOD and catalase and the increase of TBARS...
and SH-group parameters is observed that proved a lipid peroxidation disorder.

L-arginine in the standard therapy facilitates the correction of lipid peroxidation processes and reduces the severity of microalbuminuria in patients with diabetic kidney disease that slows down its progression.

References

Received: 2016-12-07